Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
M01AB05	ALMIRAL	G	Diclofenac sodium - 75mg/3ml	75mg/3ml	Injectable solution	415,247 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 1mg	1mg	Capsule, prolonged release	L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 3mg	3mg	Capsule, prolonged release	L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 3mg	3mg	Capsule, prolonged release	68,645,618 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 1mg	1mg	Capsule, prolonged release	25,729,044 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 5mg	5mg	Capsule, prolonged release	85,485,667 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 0.5mg	0.5mg	Capsule, prolonged release	13,297,758 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 80mg/4ml	80mg/4ml	Injectable concentrated solution	11,127,864 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 162mg/0.9ml	162mg/0.9ml	Injectable solution	79,959,812 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 200mg/10ml	200mg/10ml	Injectable concentrated solution	25,485,937 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 400mg/20ml	400mg/20ml	Injectable concentrated solution	47,925,322 L.L
L04AB04	ABRILADA	BioTech	Adalimumab - 40mg	40mg	Injectable solution	40,259,574 L.L
L04AB04	ABRILADA	BioTech	Adalimumab - 40mg	40mg	Injectable solution	40,259,574 L.L
L04AB04	ADALIREL	BioTech	Adalimumab - 40mg	40mg	Injectable solution	7,805,376 L.L
L04AB04	ADALIREL	BioTech	Adalimumab - 40mg	40mg	Injectable solution	L.L
L04AB01	ALTEBREL	BioTech	Etanercept - 50mg/1ml	50mg/1ml	Injectable solution	L.L
L04AB01	ALTEBREL	BioTech	Etanercept - 50mg/1ml	50mg/1ml	Injectable solution	14,833,767 L.L
L04AB01	ALTEBREL	BioTech	Etanercept - 25mg/0.5ml	25mg/0.5ml	Injectable solution	27,383,989 L.L
L04AA32	APRIVA STARTER PACK	G	Apremilast - 10mg, Apremilast - 20mg, Apremilast - 30mg		Tablet, film coated	22,154,866 L.L
L04AA32	APRIVA	G	Apremilast - 30mg	30mg	Tablet, film coated	41,455,526 L.L
L04AA31	AUBAGIO	B	Teriflunomide - 14mg	14mg	Tablet, film coated	38,773,533 L.L
L04AA31	AUBAGIO	B	Teriflunomide - 14mg	14mg	Tablet, film coated	38,773,533 L.L
L04AA13	ARAVA	B	Leflunomide - 10mg	10mg	Tablet, film coated	2,230,779 L.L
L04AA13	AROTAN	G	Leflunomide - 10mg	10mg	Tablet, film coated	1,527,949 L.L
L04AA13	ARAVA	B	Leflunomide - 20mg	20mg	Tablet, film coated	3,346,168 L.L
L04AA13	AROTAN	G	Leflunomide - 20mg	20mg	Tablet, film coated	2,014,420 L.L
L03AB07	AVONEX	BioTech	Interferon beta-1a - 30mcg/0.5ml	30mcg/0.5ml	Injectable solution	70,488,764 L.L
L02BX03	ABIRATERONE ACETATE NEAPOLIS	G	Abiraterone acetate - 250mg	250mg	Tablet	75,418,662 L.L
L02BX03	ABIRATERONE ACETATE SPC	G	Abiraterone acetate - 250mg	250mg	Tablet, film coated	92,278,660 L.L
L02BX03	ABLAX 250	G	Abiraterone acetate - 250mg	250mg	Tablet	45,056,853 L.L

...